



Flexion Therapeutics, Inc.  
Investor Relations Department  
10 Mall Road  
Suite 301  
Burlington, MA 01803  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: FLXN

Last Trade:	25.88
Trade Time:	12:58 PM ET Apr 26, 2018
Change:	0.71 <span style="color: green;">▲</span> (+2.821%)
Day Range	25.11 - 26.05
52-Week Range	16.51 - 32.25
Volume	185,820

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Flexion is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Apr 26, 2018

[Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® \(triamcinolone acetonide extended-release injectable suspension\) at Osteoarthritis Research Society International World Congress](#)

Apr 24, 2018

[Flexion Therapeutics to Present Data on ZILRETTA® \(triamcinolone acetonide extended-release injectable suspension\) at the Academy of Managed Care Pharmacy Annual Meeting 2018](#)

Apr 18, 2018

[Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® \(triamcinolone acetonide extended-release injectable suspension\) in the Journal of Bone and Joint Surgery](#)

Apr 6, 2018

[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Mar 19, 2018

[Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference](#)

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

Mar 8, 2018

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 6, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

